Anda di halaman 1dari 52

BEYOND ANTIBIOTICS -

TREATING VIRUSES & BACTERIA PATHOGENS WITH


SPECIFIC ANTIBIODIES - AND ELIMINATING THE SIDE
EFFECTS IN THE PROCESS.

JANUARY 26TH - NATIONAL MICROBIOLOGY LABORATORY


SAFE HARBOUR STATEMENTS

The information in this presentation is being made available to you and a limited number of other prospective investors on a confidential
basis, solely for the purpose of your consideration of an investment in securities under a securities purchase agreement, and such
information may not be used for any other purpose.
The information contained herein has been obtained from IGY Immune Technologies and Life Sciences Inc. (the “Company”) and from
sources believed by the Company to be reliable. The Company makes no representations or warranties, express or implied, as to the
accuracy or completeness of this information. The Company expressly disclaims any and all liability from any untrue statements or
omissions, which may be contained in this presentation or any other written or oral communication transmitted or made available to a
prospective investor. Only those particular representations made in a securities purchase agreement shall have any legal effect.
Certain statements in this presentation, such as those concerning the Company’s business strategy, products, revenues and capital
requirements, and other statements regarding matters that are not historical facts, and the Company’s financial projections included herein,
are “forward-looking” statements (as defined in the securities act of 1933). Because such forward-looking statements include
risk and uncertainties, actual results may differ materially from those expressed in or implied by such forward-looking statements.
During the course of your evaluation, all inquiries and other communications are to be made only to employees or representatives of the
Company. Accordingly, you agree not to directly or indirectly discuss with, or offer to, any third party a participation in a possible transaction
or any other form of joint investment or acquisition by you and such third party without The Company’s prior written consent.

IGY Immune Technologies & Life Sciences Inc.


PRESENTATION OVERVIEW
Overview
What We Do
Our Mission
The Trillion Dollar Health and Wellness Market
Building Immune Systems and Treating Specific World Health Problems
The Technology

Market Segments:
Medicines
Functional Foods
Agribusiness & Packaged Consumer Meat Producers
Cosmeceuticals

Corporate Structure
Strategic Timeline
Leverage Through Partnerships
Financial Forecasts
Financing Objectives
Management Team, Consultants, Advisory Board, Board Of Directors

IGY Immune Technologies & Life Sciences Inc.


WHAT WE DO

Our proprietary technology and processes makes it possible


to create health products to strengthen and supplement your
natural immune system against certain types of bacteria
viruses and other autoimmune ailments.

IGY Immune Technologies and Life Sciences specializes in the extraction of


polyclonal immunoglobulin antibodies, a type of antibodies that are derived from
chicken eggs for use as a nutraceutical for human consumption.

Immunoglobulins are powerful antibodies produced in healthy humans and other


animals to fight infections and prevent disease. Egg yolks contain immunoglobulin
IgY, the functional equivalent of immunoglobulin IgG which makes up 75% of the
immunoglobulin found in healthy human plasma.

IGY Immune Technologies & Life Sciences Inc.


OUR MISSION

IgY Immune Technologies and Life Sciences Inc. is in the business of designing specific antibodies through natural
sources and purifying them through its proprietary extraction methods. By introducing specific antibodies to the
animal kingdom, we have the ability to prevent disease, save lives and reduce our dependence on antibiotics.

By improving the body’s natural immune system, like never before, we can improve the lives of millions suffering
from viral, bacterial, and autoimmune diseases.

By preventing the spread of disease, we can save hundreds of billions in valuable tax resources; allowing
governments to redirect their resources into other areas of science, to lower the costs of healthcare systems
around the world and ultimately, bring IgY medicine to the developing world.

By arming veterinary science with improved methods to farm our agriculture and aquaculture industries, we will
create a stronger food network and at the same time, a safer drinking water system by reducing it’s over use of
antibiotic drugs.

By extending these same specific antibodies to our family pets, they can live longer, healthier lives for everyone
to enjoy.

By putting into effect the knowledge of immunologists and microbiologists around the world, our scope of
science to be discovered is incredible.

By achieving all of this, our stakeholders will be pioneers in medical science and earn a valuable share in our
financial successes.

The Cure is in the Prevention. IgY for Life.

IGY Immune Technologies & Life Sciences Inc.


THE TRILLION DOLLAR HEALTH & WELLNESS MARKET

THE MARKET OPPORTUNITY

 Public health awareness continues to shift towards disease prevention


 Boosting immune systems will become an increasingly important focus
 Dietary supplements and vitamins, already used extensively, don't contain the
antibodies needed to fight off or prevent disease

IGY Immune Technologies & Life Sciences Inc.


THE TRILLION DOLLAR HEALTH & WELLNESS MARKET

IGY Immune Technologies & Life Sciences Inc.


BUILDING THE IMMUNE SYSTEM AND TREATING WORLD HEALTH PROBLEMS

80 YEARS OF ANTIBIOTICS

“In his 1945 Nobel Prize address,


Alexander Fleming warned that it
was easy to produce microbes
resistant to his discovery, penicillin.
Simply expose them to concentrations
of the drug was insufficient to kill
them.”

John Hopkins Magazine, John Hopkins University


Alexander Fleming
Discovered Penicillin, 1928

IGY Immune Technologies & Life Sciences Inc.


BUILDING THE IMMUNE SYSTEM AND TREATING WORLD HEALTH PROBLEMS

Viral Bacteria

Autoimmune

IGY Immune Technologies & Life Sciences Inc.


BUILDING THE IMMUNE SYSTEM AND TREATING WORLD HEALTH PROBLEMS

IGY Immune Technologies & Life Sciences Inc.


BUILDING THE IMMUNE SYSTEM AND TREATING WORLD HEALTH PROBLEMS

June 24, 2009

IGY Immune Technologies & Life Sciences Inc.


BUILDING THE IMMUNE SYSTEM AND TREATING WORLD HEALTH PROBLEMS

August 3, 2009

IGY Immune Technologies & Life Sciences Inc.


BUILDING THE IMMUNE SYSTEM AND TREATING WORLD HEALTH PROBLEMS

“I suffer no illusions that this will be an


easy process. It will be hard. But I also
know that nearly a century after Teddy
Roosevelt first called for reform, the cost of
our health care has weighed down our
economy and the conscience of our nation
long enough. So let there be no doubt;
health care reform cannot wait, it must
not wait, and it will not wait another year.”

- President Barack Obama, February 2009.

“Under the proposed Preservation of Antibiotics for Medical Treatment Act, or PAMTA, newly-developed
antibiotics couldn’t be given to farm animals unless they were sick. The casual use of already-established
drugs would be restricted.”

- Brandon Keim, Wired Magazine, July 21, 2009

IGY Immune Technologies & Life Sciences Inc.


BUILDING THE IMMUNE SYSTEM AND TREATING WORLD HEALTH PROBLEMS

Focusing in the immune system is


a natural evolution in fight against
diseases. Medical science is
recognizing the importance of
strengthening innate immune
system and reducing reliance on
antibiotics.

IGY Immune Technologies & Life Sciences Inc.


THE TECHNOLOGY

Breakthrough

IRI’s ground-breaking technology opens


the wide doorway to a whole new
science.

IGY Immune Technologies & Life Sciences Inc.


THE TECHNOLOGY

IgY Works on Both Viral and Bacteria Infections

Viral infections include: Bacterial infections include:

 All colds and flu  Strep throat


 Most coughs  Urinary tract infections
 Most sore throats, and  Most ear infections
 Usually involve several  Some sinus infections, and
parts of the body  Are usually localized at a
single point in the body

IGY Immune Technologies & Life Sciences Inc.


THE TECHNOLOGY
THE PROCESS

Antibody Extraction
IGY Immune Technologies & Life Sciences Inc

High Resolution Yolk Byproducts IG Antibodies


(Patented)

IGY Immune Technologies & Life Sciences Inc.


THE TECHNOLOGY
ANTIBODY YIELD FROM HENS

 A laying hen can produce approximately 300 eggs annually and the volume
of one egg yolk is approximately 15 ml.

 This could supply close to 100g of antibody per hen per year.

 Each Eggs contain approximately 3-5mg IgY per ml of yolk (70-100mg of


total IgY antibody depending upon the size of the egg)

 Of this total and depending on the concentration level required for


commercial effectiveness, our technology can generate as little as10% or as
much as 75% antibody against a specific antigen.

IGY Immune Technologies & Life Sciences Inc.


THE TECHNOLOGY

ADVANTAGES OF ANTIBODIES FROM EGG YOLKS OVER MAMMALIAN ANTIBODIES


a. A single egg contains as much antibody as an average bleed from a rabbit. In addition,
egg collection is simple and noninvasive. Eggs are generally laid on a daily basis,
whereas a rabbit may only be bled once every 2-3 weeks.

b. Chickens require only a one month immunization regimen to obtain high titers of
polyclonal antibody. To ensure a rabbit is producing high titers of antibody, the
immunization procedure requires up to 2-3 months.

c. Similar amounts of antigen are required to immunize chickens and rabbits, but daily egg
collection occurs over a month and titers generally remain high during this period. A
rabbit may be bled only once every 2-3 weeks and the amount of antibody contained in
the sera is equivalent to the amount of antibody in a single egg.

d. Because the phylogenetic distance between birds and mammals is great, chickens are
very useful for producing antibodies against conserved mammalian proteins. Typically, 1-
5% of rabbit sera will be comprised of antibodies against a specific mammalian antigen.
About 2-10% of a chicken egg yolk is comprised of antigen-specific antibodies. In
addition, very highly conserved mammalian proteins sometimes fail to elicit an immune
response in rabbits but antibodies against these proteins are often successfully produced
in the avian system.

IGY Immune Technologies & Life Sciences Inc.


THE PROCESS OF MAKING IGY – ON A COMMERCIAL SCALE

 160,000
eggs per
day.
 ONE
KILO of
50%
Pure IgY
350
birds =
10,500
eggs

IGY Immune Technologies & Life Sciences Inc.


THE PROCESS OF MAKING IGY – ON A COMMERCIAL SCALE

Eggs are
broken at a
CFIA egg
station…

IGY Immune Technologies & Life Sciences Inc.


THE PROCESS OF MAKING IGY – ON A COMMERCIAL SCALE

… then mixed
with water and
centrifuged to
create a Water
Soluble
Fraction,
containing the
desired IgY.

IGY Immune Technologies & Life Sciences Inc.


THE PROCESS OF MAKING IGY – ON A COMMERCIAL SCALE
•The prototype
facility was over
$10 million in
design and
installation.
•Capable of
producing up to
2,000 kg per
month of IgY.

IGY Immune Technologies & Life Sciences Inc.


ISOLATION OF IGY FROM EGG YOLK
Results: SDS-PAGE

IgY

Rm rt+w1 w2 el

IGY Immune Technologies & Life Sciences Inc.


ISOLATION OF IGY FROM EGG YOLK
Results: Size exclusion chromatography
IgY
App. 60 % purity

IGY Immune Technologies & Life Sciences Inc.


THE TECHNOLOGY

EFFECTIVENESS OF IGY FOR SALMONELLA

IGY Immune Technologies & Life Sciences Inc.


THE TECHNOLOGY

COMPETITIVE ADVANTAGES

 Higher concentration of IgY (traditional 5% purity vs. 25% or >)


 Fats are removed
 No Cholesterol
 Pharmaceutical grade
 Tasteless and odorless
 Can be “designed” for a variety of applications
 Can be used in an aerosol
 No competitive technology
 Comprehensive patents on intellectual property
.

IGY Immune Technologies & Life Sciences Inc.


THE TECHNOLOGY

INTELLECTUAL PROPERTY PROTECTION

Our Company’s value lies in our ability


to continuously generate new IP
protection for IgY. We are regularly
adding new patents to our existing
portfolio.

Patent approvals are sought


internationally for ingredients and
processes and for products that are
developed.

We have chosen not patent certain key


elements of our process for added
protection.

IGY Immune Technologies & Life Sciences Inc.


THE TECHNOLOGY

MANUFACTURING & PRODUCTION

 Control over egg supply chain


 Eggs are the most economical and practical solution as chickens lay eggs
regularly, so there is a continual source of antibody
 Agreements secured with suppliers
 economical and practical solution deal to the leftover egg byproduct
.

IGY Immune Technologies & Life Sciences Inc.


MARKET SEGMENTS

COMMERCIAL APPLICATIONS
Our commercial applications fall across 4 primary sectors which means we can grow
our product base and revenue streams against any cyclical variations.

IGY Immune Technologies & Life Sciences Inc.


MARKET SEGMENTS: MEDICINES

IGY SPECIFIC - CLOSTRIDIUM DIFFICILE (C.DIFFICLE)

Ig(Y) specific for Clostridium Difficile Bacteria.

Under development with Dr. Michelle Alfa, University of


Manitoba and St. Boniface Hospital

Expected combined phase I and II trials to be completed


within 24 months, and a marketable pharmaceutical ready
for 2012

Expected to generate over a Billion dollars of revenue in


North America alone.

Dr. Alfa has already proven the viability of generating the


antigens from the eggs, the problem remained commercial
ability to produce an Ig(Y) Specific, which has now been
solved.

IGY Immune Technologies & Life Sciences Inc.


MARKET SEGMENTS: MEDICINES

CLOSTRIDIUM DIFFICILE (C.DIFFICLE)


LETHAL HOSPITAL BUG CASES ROCKET, UNITED KINGDOM

Potentially lethal cases of C. Difficile “rocketed” from 1990s to 2004

Cases had increased from 1,000 in 1990 to over 35,000 in 2003

44,488 cases of C. Difficile in > 65 year olds in 2004.

Good new stats here on C. Dif. with 7,000 cases per day, and 300
mortalities per day.

$51.5 million in health care costs, per day in the United States. That is
$18.8 Billion per year in costs. This just for C. Diff. not to mention MSRA.

A single occurrence of CDI adds about $3,700 to a hospital bill and can
mean three or more additional nights in the hospital.
BBC News. http://news.bbc.co.uk/2/hi/health/4186834.stm

IGY Immune Technologies & Life Sciences Inc.


MARKET SEGMENTS: FUNCTIONAL FOODS

IGY Immune Technologies & Life Sciences Inc.


MARKET SEGMENTS: FUNCTIONAL FOODS

PHARMA FOODS INTERNATIONAL CO., LTD

Multi-Million dollar letter of intent signed December 25th,


2008.

Pharma Foods markets a variety of Ig(Y) products.

Majority of Asians and Mexicans suffer from HP bacteria.

Second part of agreement to produce H5N1 (avian flu)


antibody.

Current processes provide approximately 5% purity of H. Pylori


IGY. Our process provides 50-75% purity of H. Pylori IGY.

Discussions with Pharma Company in China to produce a H.Pylori


pharmaceutical.

IGY Immune Technologies & Life Sciences Inc.


MARKET SEGMENTS: FUNCTIONAL FOODS

http://www.pharmafoods.co.jp

IGY Immune Technologies & Life Sciences Inc.


MARKET SEGMENTS: AGRIBUSINESS AND PACKAGED CONSUMER MEATS

IGY Immune Technologies & Life Sciences Inc.


MARKET SEGMENTS: COSMECEUTICALS

THE COSMECEUTICALS MARKET

 The cosmeceuticals market is forecasted to reach $21 billon by 2012


 Sales of natural body care products are thriving with 14% growth in 2007
and annual compound growth of 57% since 2004
 Skin care, hair care and colour cosmetic cosmeceuticals showed an overall
25% gain in the retail sector between 2003 and 2007

IGY Immune Technologies & Life Sciences Inc.


MARKET SEGMENTS: COSMECEUTICALS

A natural and a safe alternate to Antibiotic


Treatment for Acne

Our Acne Product is an antibody tailored skin treatment. The antibody is made in a similar way to
that of making a vaccine. The antibody is a specific immunoglobulin (IgY) that we produce targets
for Propionibacterium Acnes or P. Acnes for short. The exact cause for all forms of acne (pimples,
whiteheads, blackheads, mild and severe lesions) is not known but researchers believe there are
many related factors. However, common to all forms of acne is the culprit, P. Acnes. Our acne
treatment inactivates P. Acnes and thereby removes the major cause of skin inflammation and
disease. Without P. Acnes the skin will heal and new lesions will not occur.

Before After
Treatment Treatment

IGY Immune Technologies & Life Sciences Inc.


MARKET SEGMENTS: COSMECEUTICALS

The IGY Skincare Program is a complete


system of three products

1. Cleansing Mousse : Contains Natural Oceanic Clay, Herbs and Vitamin E to protect and
maintain the skin’s health while natural emulsifiers and scrubbing beads remove makeup
and soils effectively.

2. Natural Oceanic Clay mask with IgY: Anti-Acne Clay Mask with IgY helps combat
blemishes and blackheads in a double action through the combined forces of our Natural
Oceanic Clay and APA - IgY.

3. Moisturizing Cream with IgY: This anti-acne moisturizing cream is formulated as a


treatment for prevention of acne skin infections caused by Propionibacterium acne. Our
unique antibody treatment – APA-IgY (Anti Propionibacterium Acnes-IgY) penetrates the
skin and destroys the Propionibacterium Acne-bacteria that is common among all forms of
acne, and prevents the appearing of blackheads and blemishes. Panthenol and Sunflower
Oil moisturizes the skin. This beneficial formula completes the treatment of acne while
maintaining the healthy condition of the skin.

IGY Immune Technologies & Life Sciences Inc.


MARKET SEGMENTS: COSMECEUTICALS

INFOMERCIAL STRATEGY "Proactiv has become a phenomenon by transforming


the way consumers think about pimples. The brand
captured public attention by hiring stars for its
infomercials like Vanessa Williams, Jessica Simpson
and Sean Combs to lay bare their valiant struggles to
attain flawless skin, effectively turning acne into a
celebrity malady. But the company’s real innovation
was repositioning mild breakouts from a routine
annoyance that a dab of Clearasil might fix to a
preventable condition, like cavities, requiring vigilant
daily upkeep.
The brand now has more than five million active
customers and annual worldwide sales of about $850
million, 70 percent of which are in the United States.
“Right now, we own acne,” said Greg Renker, a chief
executive of Guthy-Renker, the direct-response
television company that sells Proactiv“
New York Times, October 2007

IGY Immune Technologies & Life Sciences Inc.


STRATEGIC TIMELINE

IGY Immune Technologies & Life Sciences Inc.


LEVERAGE RESOURCES THROUGH PARTNERSHIPS

 GloBayne Marketing
International
 FedNor
 Maple Leaf Foods
 Provincial Health Care
Ministries
 National Research
Counsel, IRAP program
 Ironwood Clay Company

IGY Immune Technologies & Life Sciences Inc.


THE OPPORTUNITY LIES IN OUR LEADERSHIP

 While the current budget is set for cosmeceutical and


nutraceutical applications, the opportunity for the National
Microbiology Lab lies in a joint effort to create the first
pharmaceutical IgY product.
 A C. Difficile IgY Specific remains our top priority.
 Much of the phase I & II clinical work has been completed
by the SBRC.
 Steps to move forward include acquiring a government
approved vaccine for C. Difficile, producing a test sample of
IgY Specific C. Difficile, completing the requirements for
human testing.

IGY Immune Technologies & Life Sciences Inc.


THE OPPORTUNITY LIES IN OUR LEADERSHIP
ELISA C.difficile
0.8

0.7

0.6

0.5 Sigma
A(4 IRI 27067
05
nm 0.4 IRI 07067
)
IRI 27067 Eggcellent Extract
blank (diluent)
0.3
3% gelatin coated vs 27067 extract
3% gelatin coated vs 27067
0.2

0.1

0
62.5 125 250 500 1000 2000 4000 8000

[IgY] (ng/mL)

IGY Immune Technologies & Life Sciences Inc.


IGY C. DIFFICILE SPECIFIC – SAVE LIVES & MONEY

 Currently, 300 people per day die as a result of C. Difficile


related causes in the USA everyday.
 The cost to the US health-care system is $51.5 million per
day.
 The average cost of a stay in a Canadian hospital is $1,350,
escalating to $2,500 per day in an isolation room.
 We estimate that at 75% of the patient load in a health
care facility taking C. difficile IgY Specific antibodies, at
$3.50 per day would save roughly $16 billion in health care
costs in North America and 120,000 lives annually.

IGY Immune Technologies & Life Sciences Inc.


IMAGINE THE POSSIBILITIES
 Candida albicans
 Rotavirus

 Streptococcus mutans

 Listeria monocytogenes

 Parvovirus

 Celiac and colitis

 Cystic fibrosis

 Staphylococcal enterotoxin B

 As a tool in proteomics

IGY Immune Technologies & Life Sciences Inc.


MANAGEMENT TEAM

Terry N. Dyck President, CEO

Sharad Mistry Chief Financial Officer

John Mason Chief of Research

David Mason Chief of Operations

IGY Immune Technologies & Life Sciences Inc.


CONSULTANTS

Dr. Stu Richie Canadian Poultry Consultants Ltd.

Roger Upton, President Ironwood Clay Company

Ian Cooke Facilities Engineer

Ameann DeJohn Ameann Solutions, CA

Bob Jones, Principle Scientia Advisors

John Henderson, President Brain Box Communications

IGY Immune Technologies & Life Sciences Inc.


ADVISORY BOARD

Ron Bayne President of GloBayne

Dr. John Webb Director of Science, Maple Leaf Foods

Ken Boshcoff Governmental Affairs

Dr. Frank Mauro Periodontist

Dr. Sheetal Sapra Dermatology

Dr. Keith Ly Dermatology

Dr. Jeanette Jacknin Dermatology

IGY Immune Technologies & Life Sciences Inc.


LEGAL TEAM

Michael Strickland, corporate affairs Bust & Partners, Thunder Bay, ON

Jay Lefton, securities law Ogilvy Renault, Toronto

Stephen Burri, Intellectual Property Miller Thomson, Vancouver

John Cameron, BDO Dunwoody Auditors, Thunder Bay

IGY Immune Technologies & Life Sciences Inc.


BOARD OF DIRECTORS

Terry N. Dyck, President and CEO

Kevin Nephin

Dr. Brian Scott

Rashid Ahmed

Sharad Mistry

IGY Immune Technologies & Life Sciences Inc.


QUESTIONS AND ANSWERS

A New Beginning…
Boosting the Immune System,
Prevention is the Cure.

IGY Immune Technologies & Life Sciences Inc.